Linksbridge

Serum Institute of India says it needs less than a month to manufacture doses of an experimental vaccine ready for testing against the rare species of Ebola spreading in DRC and Uganda.

More on efforts to combat Bundibugyo virus and other pharma news important to global health in this week's highlights.

Linksbridge Pharma News: this week's highlights Ebola outbreak: race for vaccines and drugs begins As a rare species of Ebola spreads in DRC and Uganda, Oxford University and the Serum Institute of India (with support from CEPI) have entered an “emergency response arrangement” to develop and manufacture an investigational vaccine ready for te...

Armed with a fresh $108 million funding boost, South Africa-based Biovac is gearing up to build the continent's first end-to-end multivaccine manufacturing facility in Cape Town. This week's issue spotlights Biovac's ambitious push, Switzerland's newly unredacted Covid vaccine contracts, data from an early-stage chikungunya mAb trial, and more.

Linksbridge Pharma: this week's highlights Biovac nabs $108M for end-to-end vaccine manufacturing Africa’s first end-to-end multivaccine manufacturing facility is coming to Cape Town. The E.